Internal medicine

Adverse effect

Eculizumab

Disease

Rituximab

Pathogenesis

Complement system

Alternative complement pathway

Antibody

Cyclophosphamide

Immunology

Anti-neutrophil cytoplasmic antibody

Vasculitis

Chemotherapy

Microscopic polyangiitis

ANCA-Associated Vasculitis

Medicine

Pharmacology

Frontiers in Immunology

Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activation of alternative complement pathway plays an important role in the pathogenesis of AAV. Avacopan (C5a receptor inhibitor) was demonstrated to have at least similar efficacy and better safety (in terms of corticosteroid-related adverse events) compared with high-dose corticosteroids in the induction treatment of AAV. Other modes of the inhibition of alternative complement pathway are currently tested in AAV or could be considered on the basis of the experience in other glomerular diseases.

Complement Inhibition in ANCA-Associated Vasculitis